Hepatitis B virus treatment beyond the guidelines: Special populations and consideration of treatment withdrawal

Therapeutic Advances in Gastroenterology

Volumn 7, Issue 4, 2014, Pages 148-155

  Vallet Pichard, Anais ^a   Pol, Stanislas ^b  

^a INSTITUT COCHIN   (France)

^b Departement depatologie   (France)

Author keywords

chronic hepatitis; hepatitis B virus; hepatitis B virus related cirrhosis; hepatitis B virus therapies; hepatocellular carcinoma; nucleos(t)ide analogues; pegylated interferon

Indexed keywords

ADEFOVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; FLUDARABINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA; PLACEBO; TELBIVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIRUS DNA;

ACUTE HEPATITIS; ANTIBODY TITER; ANTIVIRAL THERAPY; BLOOD TOXICITY; CHRONIC HEPATITIS; COGNITIVE DEFECT; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG SAFETY; FETUS RISK; FLU LIKE SYNDROME; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER GRAFT; MIXED INFECTION; NEUROLOGIC DISEASE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SEROCONVERSION; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 84904803311     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X14524614     Document Type: Review

References (46)

1. Benaboud S. Pruvost A. Coffie P. Ekouévi D. Urien S. Arrivé E. et al. (2011) Breast milk concentrations of tenofovir and emtricitabine in HIV-1 infected women in Abidjan TEmAA Step 2 (ANRS 12109). Antimicrob Agents Chemother 55: 1315–1317.
2. Boni C. Penna A. Ogg G. Bertoletti A. Pilli M. Cavallo C. et al. (2001) Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33: 963–971.
3. Brown R. Verna E. Pereira M. Tilson H. Aguilar C. Leu C. et al. (2012) Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. J Hepatol 57: 953–959.
4. Brunetto M. Oliveri F. Colombatto P. Moriconi F. Ciccorossi P. Coco B. et al. (2010) Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 139: 483–490.
5. Chan H., Chan C. Hui A. Chan S. Poordad F. Chang T. et al. (2013) Tenofovir DF (5TDF) compared to emtricitabine (FTC)/TDF in HBeAg-positive, chronic hepatitis B (CHB) virus-infected patients in the immune tolerant (IT) phase. J Hepatol 58 (Suppl. 1): S45.
6. Chang T. Gish R. de Man R. Gadano A. Sollano J. Chao Y. et al. (2006)A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354: 1001–1010.
7. Chaung K. Ha N. Trinh H. Garcia R. Nguyen H. Nguyen K. et al. (2012) High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastroenterol 46: 865–870.
8. Deng M. Zhou X. Gao S. Yang S. Wang B. Chen H. et al. (2012) The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. Virol J 9: 185.
9. EASL (2012) EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57: 167–185.
10. Fontaine H. Kahi S. Chazallon C. Bourgine M. Varaut A. Buffet C. et al. (2014) Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in treatment of chronic hepatitis B: a randomized trial – ANRS HB 02 VAC-ADN. Gut, in press.
11. Garg H. Sarin S. Kumar M. Garg V. Sharma B. Kumar A. (2011) Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 53: 774–780.
12. Hadziyannis S. Sevastianos V. Rapti I. Vassilopoulos D. Hadziyannis E. (2012) Sustained responses and loss of AgHBs in AgHBe-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 143: 629.e1–636.e1.
13. Han G. Cao M. Zhao W. Jiang H. Wang C. Bai S. et al. (2011 a) A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 55: 1215–1221.
14. Han L. Zhang H. Xie J. Zhang Q. Wang H. Cao G. (2011 b) A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol 17: 4321–4333.
15. Lai C. Gane E. Liaw Y. Hsu C. Thongsawat S. Wang Y. et al. (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357: 2576–2588.
16. Lampertico P. Law Y. (2012) New perspectives in the therapy of chronic hepatitis B. Gut 61(Suppl. 1): i18-i24.
17. Lampertico P. Vigano M. Cheroni C. Facchetti F. Invernizzi F. Valveri V. et al. (2012) IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 57: 890-896.
18. Liaw Y. Jia J. Chan H. Han K. Tanwandee T. Chuang W. et al. (2011) Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis e antigen seroconversion rates in hepatitis B virus genotype B or C. Hepatology 54: 1591–1599.
19. Liaw Y. Kao J. Piratvisuth T. Chan H. Chien R. Lin C. et al. (2012) Asian-Pacific consensus statement on the management of chronic hepatitis B. Hepatol Int 6: 531–561.
20. Lee C. Gong Y. Brok J. Boxall E. Gluud C. (2006) Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 332: 328–336.
21. Lee H. Lee H. Hwang J. Sohn J. Jang J. Han K. et al. (2010) Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 51: 415–421.
22. Lok A. McMahon B. (2007) Chronic hepatitis B. Hepatology 45: 507–539.
23. Lok A. McMahon B. (2009) Chronic hepatitis B: update 2009. Hepatology 50: 661–662.
24. Mandala M. Fagiuoli S. Francisci D. Bruno R. Merelli B. Pasulo L. et al. (2013) Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis. Crit Rev Oncol Hematol 87: 12–27.
25. Marcellin P. Gane E. Buti M. Afdhal N. Sievert W. Jacobson I. et al. (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381: 468–475.
26. Marcellin P. Heathcote E. Buti M. Gane E. de Man R. Krastev Z. et al. (2008) Tenofovir disoproxilfumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359: 2442–2455.
27. Nguyen N. Nguyen V. Trin H. Lin B. Nguyen M. (2013) Treatment eligibility of patients with chronic hepatitis B initially ineligible for therapy. Clin Gastroenterol Hepatol 11: 565–571.
28. Ono A. Suzuki F. Kawamura Y. Sezaki H. Hosaka T. Akuta N. et al. (2012) Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol 57: 508–514.
29. Petersen J. Buggisch P. Stoehr A. Hinrichsen H. Mauss S. Berg T. et al. (2011) Stopping long-term nucleos(t)ide analogue therapy before HBsAg loss or seroconversion in HBeAg-negative CHB patients: experience from five referral centers in Germany. Hepatology 54: 1417.
30. Piroth L. Mahy S. Pol S. Carrat F. Sene D. Etienne M. et al. (2011) Current management and recommendations on hepatitis B therapy in HIV-coinfected patients. Hepatol Int 7: 437–442.
31. Pol S. Lampertico P. (2012) First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice. J Viral Hepat 19: 377–386.
32. Reijnders J. Perquin M. Zhang N. Hansen B. Janssen H. (2010) Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 139: 491–498.
33. Rijckborst V. Hansen B. Ferenci P. Brunetto M. Tabak F. Cakaloglu Y. et al. (2012) Validation of a stopping rule at week 12 using HBsAg and HBV DNA foe HBeAg-negative patients treated with peginterferon alpha-2a. J Hepatol 56: 1006–1011.
34. Sonneveld M. Wong V. Woltman A. Wong G. Cakaloglu Y. Zeuzem S. et al. (2012) Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 142: 513.e1–5220.e1.
35. Tran T. (2009) Management of hepatitis B in pregnancy: weighing the options. Cleve Clin J Med 76: S25–S29.
36. Tseng T. Liu C. Chen C. Yang H. Su T. Wang C. et al. (2013 a) Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers. J Infect Dis 208: 584–593.
37. Tseng T. Liu C. Su T. Yang H. Wang C. Chen C. et al. (2012 a) Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. J Infect Dis 206: 1521–1531.
38. Tseng T. Liu C. Yang H. Su T. Wang C. Chen C. et al. (2012 b) High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 142: 1140–1149.
39. Tseng T. Liu C. Yang H. Su T. Wang C. Chen C. et al. (2013 b) Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 57: 441–450.
40. Tujios S. Lee W. (2013) Update in the management of chronic hepatitis B. Curr Opin Gastroenterol 29: 250–256.
41. Wen W. Chang M. Zhao L. Ni Y. Hsu H. Wu J. et al. (2013) Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for interventions. J Hepatol 59: 24–30.
42. Wong V. Wong G. Yan K. Chim A. Chan H. Tse C. et al. (2010) Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51: 1945–1953.
43. Wu X. Xin Z. Zhu X. Pan L. Li Z. Li H. et al. (2012) Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese. Antiviral Res 93: 297–300.
44. Xie F. Yan L. Lu J. Zheng T. Shi C. Ying J. et al. (2013) Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis. PloS ONE 8: e54773.
45. Zachou K. Sarantopoulos A. Gatselis N. Vassiliadis T. Gabeta S. Stefos A. et al. (2013) Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: a hidden threat. World J Hepatol 5: 387–392.
46. Zoulim F. Mason W. (2012) Reasons to consider earlier treatment of chronic HBV infections. Gut 61: 333–336.